An IND has already been submitted and accepted for all clinical trials. No NDAs have. In between, Expanded Access is a possibility provided the various rules are satisfied.
Expand Access of course requires an IND for FDA to understand and accept a new drug before it goes in the clinic.
Market Data 
Markets 
AI
